Multimodality Treatments of HPV-related Lesions of the Female Genital Tract

Launched by FONDAZIONE IRCCS ISTITUTO NAZIONALE DEI TUMORI, MILANO · Jul 3, 2023

Keywords

ClinConnect Summary

This clinical trial is studying the best ways to treat women with lesions caused by human papillomavirus (HPV), which can lead to cervical cancer and other vaginal diseases. HPV is a common virus, and while many women will not develop serious problems from it, some may experience cervical dysplasia, a condition where cells in the cervix are abnormal and can potentially develop into cancer. The trial aims to identify important factors that might help predict which women are at risk for ongoing or returning dysplasia after treatment, as managing these risks is crucial for preventing cervical cancer.

Women aged 65 to 74 with HPV-related diseases may be eligible to participate in this study, provided they consent to join and do not withdraw from the trial. Participants will receive careful monitoring and treatment options tailored to their specific needs based on their risk factors. This research is essential because it seeks to improve treatment outcomes and may help prevent complications related to surgeries that could affect a woman's ability to have children in the future.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • Patients with HPV related disease
• Exclusion Criteria:
• • consent withdrawal